| First Author | Hayashi M | Year | 2012 |
| Journal | Nature | Volume | 485 |
| Issue | 7396 | Pages | 69-74 |
| PubMed ID | 22522930 | Mgi Jnum | J:183995 |
| Mgi Id | MGI:5319714 | Doi | 10.1038/nature11000 |
| Citation | Hayashi M, et al. (2012) Osteoprotection by semaphorin 3A. Nature 485(7396):69-74 |
| abstractText | The bony skeleton is maintained by local factors that regulate bone-forming osteoblasts and bone-resorbing osteoclasts, in addition to hormonal activity. Osteoprotegerin protects bone by inhibiting osteoclastic bone resorption, but no factor has yet been identified as a local determinant of bone mass that regulates both osteoclasts and osteoblasts. Here we show that semaphorin 3A (Sema3A) exerts an osteoprotective effect by both suppressing osteoclastic bone resorption and increasing osteoblastic bone formation. The binding of Sema3A to neuropilin-1 (Nrp1) inhibited receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation by inhibiting the immunoreceptor tyrosine-based activation motif (ITAM) and RhoA signalling pathways. In addition, Sema3A and Nrp1 binding stimulated osteoblast and inhibited adipocyte differentiation through the canonical Wnt/beta-catenin signalling pathway. The osteopenic phenotype in Sema3a-/- mice was recapitulated by mice in which the Sema3A-binding site of Nrp1 had been genetically disrupted. Intravenous Sema3A administration in mice increased bone volume and expedited bone regeneration. Thus, Sema3A is a promising new therapeutic agent in bone and joint diseases. |
